



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
PO Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,741	06/21/2001	Elmar-Reinhold Burchardt	LE A 33 256	2024

7590 06/25/2003

Jeffrey M Greenman  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

[REDACTED] EXAMINER

RUSSEL, JEFFREY E

[REDACTED] ART UNIT

[REDACTED] PAPER NUMBER

1654

DATE MAILED: 06/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/830,741	BURCHARDT ET AL.
	Examiner Jeffrey E. Russel	Art Unit 1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM  
THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 27 August 2001 and 28 May 2002.

2a) This action is **FINAL**.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 1-4 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) 1 and 4 is/are allowed.

6) Claim(s) 2 and 3 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 21 June 2001 is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

1) Notice of References Cited (PTO-892)      4) Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)      5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5,13      6) Other: \_\_\_\_\_

1. The Sequence Listing filed February 26, 2002 has been approved.
2. The abstract of the disclosure is objected to because it is insufficiently detailed with respect to the particular therapeutic uses of the phosphinate peptide analogs. Correction is required. See MPEP § 608.01(b).
3. The disclosure is objected to because of the following informalities: A Brief Description of the Drawings is missing from the specification (see 37 CFR 1.74), or possibly such a heading needs to be inserted at page 12, line 6, of the specification. The beginning parenthesis at page 3, line 17, and the end bracket at page 3, line 19, are unmatched. A SEQ ID NO needs to be inserted after the amino acid sequence at page 8, lines 20-21. See 37 CFR 1.821(d). Also, in the sequence, the residue abbreviation "Gln" is misspelled. At page 14, line 10, the end parenthesis after "phenylethyl" is unmatched. Appropriate correction is required.
4. Claims 2 and 3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 2 and 3 are contradictory because the formulas recited therein require a particular stereoconfiguration, but then the last line of each claim indicates that alternative stereoisomers and enantiomers can be used. It is not clear if the compounds to be used in these claims are to be limited to any stereoconfiguration or not. If not, it is not clear how dependent claim 2 differs in scope from independent claim 1.
5. Claims 1 and 4 are allowed. Claims 2 and 3 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, set forth in this Office action. While the prior art of record teaches the active agents required by Applicants' claimed methods (see, e.g., references R1 and R20 of Applicants' Information Disclosure Statements),

the prior art of record does not teach or suggest the use of these active agents to treat fibrotic diseases. Particularly with respect to the Yiallouros et al article (Biochem. J., Vol. 331, pages 375-379), the reference describes its compounds as possibly being useful in the design of drugs directed towards members of the astacin family (see, e.g., the Abstract and page 378, column 2, last paragraph), but does not provide any indication or reasonable expectation that the compounds described therein would themselves be useful in the therapeutic treatment of any disease involving a member of the astacin family.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (703) 308-3975. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Brenda Brumback can be reached at (703) 306-3220. The fax number for Art Unit 1654 for formal communications is (703) 305-3014; for informal communications such as proposed amendments, the fax number (703) 746-5175 can be used. The telephone number for the Technology Center 1 receptionist is (703) 308-0196.

*J. E. Russel*  
Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

JRussel

June 24, 2003